Literature DB >> 28446665

Dense Array of Spikes on HIV-1 Virion Particles.

Armando Stano1, Daniel P Leaman1, Arthur S Kim1, Lei Zhang1, Ludovic Autin2, Jidnyasa Ingale1, Syna K Gift1, Jared Truong2, Richard T Wyatt1,3, Arthur J Olson2, Michael B Zwick4.   

Abstract

HIV-1 is rare among viruses for having a low number of envelope glycoprotein (Env) spikes per virion, i.e., ∼7 to 14. This exceptional feature has been associated with avoidance of humoral immunity, i.e., B cell activation and antibody neutralization. Virus-like particles (VLPs) with increased density of Env are being pursued for vaccine development; however, these typically require protein engineering that alters Env structure. Here, we used instead a strategy that targets the producer cell. We employed fluorescence-activated cell sorting (FACS) to sort for cells that are recognized by trimer cross-reactive broadly neutralizing antibody (bnAb) and not by nonneutralizing antibodies. Following multiple iterations of FACS, cells and progeny virions were shown to display higher levels of antigenically correct Env in a manner that correlated between cells and cognate virions (P = 0.027). High-Env VLPs, or hVLPs, were shown to be monodisperse and to display more than a 10-fold increase in spikes per particle by electron microscopy (average, 127 spikes; range, 90 to 214 spikes). Sequencing revealed a partial truncation in the C-terminal tail of Env that had emerged in the sort; however, iterative rounds of "cell factory" selection were required for the high-Env phenotype. hVLPs showed greater infectivity than standard pseudovirions but largely similar neutralization sensitivity. Importantly, hVLPs also showed superior activation of Env-specific B cells. Hence, high-Env HIV-1 virions, obtained through selection of producer cells, represent an adaptable platform for vaccine design and should aid in the study of native Env.IMPORTANCE The paucity of spikes on HIV is a unique feature that has been associated with evasion of the immune system, while increasing spike density has been a goal of vaccine design. Increasing the density of Env by modifying it in various ways has met with limited success. Here, we focused instead on the producer cell. Cells that stably express HIV spikes were screened on the basis of high binding by bnAbs and low binding by nonneutralizing antibodies. Levels of spikes on cells correlated well with those on progeny virions. Importantly, high-Env virus-like particles (hVLPs) were produced with a manifest array of well-defined spikes, and these were shown to be superior in activating desirable B cells. Our study describes HIV particles that are densely coated with functional spikes, which should facilitate the study of HIV spikes and their development as immunogens.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; antigenicity; broadly neutralizing antibodies; cellPACK; electron microscopy; envelope glycoprotein; fluorescence-activated cell sorting; vaccine design; viral infectivity; virus-like particles

Mesh:

Substances:

Year:  2017        PMID: 28446665      PMCID: PMC5487557          DOI: 10.1128/JVI.00415-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  87 in total

1.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

3.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

4.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

5.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

6.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

7.  Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface.

Authors:  Jonathan D Steckbeck; Chengqun Sun; Timothy J Sturgeon; Ronald C Montelaro
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

8.  Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail.

Authors:  Takeo Kuwata; Takaki Kaori; Ikumi Enomoto; Kazuhisa Yoshimura; Shuzo Matsushita
Journal:  Front Microbiol       Date:  2013-05-14       Impact factor: 5.640

9.  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.

Authors:  Kwinten Sliepen; Gabriel Ozorowski; Judith A Burger; Thijs van Montfort; Melissa Stunnenberg; Celia LaBranche; David C Montefiori; John P Moore; Andrew B Ward; Rogier W Sanders
Journal:  Retrovirology       Date:  2015-09-26       Impact factor: 4.602

10.  IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.

Authors:  Jingyou Yu; Minghua Li; Jordan Wilkins; Shilei Ding; Talia H Swartz; Anthony M Esposito; Yi-Min Zheng; Eric O Freed; Chen Liang; Benjamin K Chen; Shan-Lu Liu
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

View more
  30 in total

1.  Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.

Authors:  Jeremiah D Heredia; Jihye Park; Hannah Choi; Kevin S Gill; Erik Procko
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

2.  Intact Viral Particle Counts Measured by Flow Virometry Provide Insight into the Infectivity and Genome Packaging Efficiency of Moloney Murine Leukemia Virus.

Authors:  Tyler Milston Renner; Vera A Tang; Dylan Burger; Marc-André Langlois
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

3.  Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Authors:  Syna Kuriakose Gift; Daniel P Leaman; Lei Zhang; Arthur S Kim; Michael B Zwick
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

Review 4.  Molecular Mechanism of HIV-1 Entry.

Authors:  Bing Chen
Journal:  Trends Microbiol       Date:  2019-06-28       Impact factor: 17.079

5.  Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout.

Authors:  Sabine Lichtenegger; Sabine Saiger; Melina Hardt; Susanne Kulnik; Gabriel E Wagner; Barbara Kleinhappl; Karoline Assig; Andrea Zauner; Michelle Ober; Janine Kimpel; Dorothee von Laer; Kurt Zatloukal; Ivo Steinmetz
Journal:  J Clin Microbiol       Date:  2022-06-01       Impact factor: 11.677

6.  HIV-cell membrane fusion intermediates are restricted by Serincs as revealed by cryo-electron and TIRF microscopy.

Authors:  Amanda E Ward; Volker Kiessling; Owen Pornillos; Judith M White; Barbie K Ganser-Pornillos; Lukas K Tamm
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

7.  Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.

Authors:  Daniel P Leaman; Armando Stano; Yajing Chen; Lei Zhang; Michael B Zwick
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

8.  Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.

Authors:  Stefania Dispinseri; Massimiliano Secchi; Maria Franca Pirillo; Monica Tolazzi; Martina Borghi; Cristina Brigatti; Maria Laura De Angelis; Marco Baratella; Elena Bazzigaluppi; Giulietta Venturi; Francesca Sironi; Andrea Canitano; Ilaria Marzinotto; Cristina Tresoldi; Fabio Ciceri; Lorenzo Piemonti; Donatella Negri; Andrea Cara; Vito Lampasona; Gabriella Scarlatti
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

9.  Super-Resolution Fluorescence Imaging Reveals That Serine Incorporator Protein 5 Inhibits Human Immunodeficiency Virus Fusion by Disrupting Envelope Glycoprotein Clusters.

Authors:  Yen-Cheng Chen; Chetan Sood; Mariana Marin; Jesse Aaron; Enrico Gratton; Khalid Salaita; Gregory B Melikyan
Journal:  ACS Nano       Date:  2020-06-01       Impact factor: 15.881

10.  Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers.

Authors:  Alessandra Gallinaro; Maria Franca Pirillo; Yoann Aldon; Serena Cecchetti; Zuleika Michelini; Antonella Tinari; Martina Borghi; Andrea Canitano; Paul F McKay; Roberta Bona; Maria Fenicia Vescio; Felicia Grasso; Maria Blasi; Silvia Baroncelli; Gabriella Scarlatti; Celia LaBranche; David Montefiori; Mary E Klotman; Rogier W Sanders; Robin J Shattock; Donatella Negri; Andrea Cara
Journal:  NPJ Vaccines       Date:  2022-04-21       Impact factor: 9.399

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.